Monday, November 01, 2010
Company Urges FDA to Put Patients First As Regulators Implement Biosimilar Pathway
THOUSAND OAKS, Calif., Nov. 1, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.
Read the rest of this entryPosted in Press Releases
Subscribe to
Amgen RSS Feeds
Press ReleasesArchives
April 2012March 2012February 2012January 2012December 2011November 2011October 2011September 2011August 2011July 2011June 2011May 2011April 2011March 2011January 2011December 2010November 2010October 2010July 2010June 2010May 2010April 2010March 2010February 2010January 2010December 2009November 2009October 2009September 2009August 2009July 2009June 2009May 2009April 2009March 2009February 2009January 2009December 2008November 2008October 2008September 2008August 2008July 2008June 2008May 2008April 2008March 2008February 2008January 2008December 2007